Radiotherapy

New 3D imaging technology developed at University of Michigan enables real-time measurement of radiation treatment, enhancing precision and potentially minimizing off-target effects.

In a video interview, Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, spoke about two presentations on using radiation palliatively presented at ASCO Gastrointestinal Cancers Symposium.

An expert panel of pediatric cardiologists and oncologists issued its inaugural cardio-oncology guidelines for the management of pediatric patients receiving anticancer therapy.

Proton FLASH radiotherapy showed clinical feasibility in a first-in-human study of patients with cancer and painful bone metastases, according to data presented at American Society for Radiation Oncology Annual Meeting.

Long-course androgen depravation therapy extended metastasis-free survival compared with short-course ADT when added to radiotherapy after radical prostatectomy, results of the randomized phase 3 RADICALS-HD trial showed.

Physicians may overlook substantial symptoms in certain patients undergoing radiotherapy for breast cancer, especially those who are young, Black or of “other” race or ethnicity, according to a study published in JAMA Oncology.

Healio rounded up the top breast cancer coverage presented and discussed at ASCO Annual Meeting in Chicago.

Radiotherapy after induction chemotherapy improved R0 circumferential resection margin-negative resection and pathologic complete response rates among patients with pancreatic cancer without a significant increase in R0 resection rate.

Mark W. Ball, MD, spoke with Healio about an ongoing phase 2 study assessing the use of cytoreductive stereotactic hypofractionated radiotherapy along with ipilimumab and nivolumab in patients with metastatic renal cell carcinoma.

The FDA approved lutetium Lu 177 vipivotide tetraxetan for treatment of certain men with advanced prostate cancer.